In Vivo Proof of Superselective Transarterial Chemoembolization with 40-μm Drug-Eluting Beads in a Patient with Hepatocellular Carcinoma

She, Hoi Lam; Burgmans, Mark C.; Coenraadm, Minneke; Saraqueta, Arantza Farina

doi:10.1007/s00270-015-1154-8

Cited by 4 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding clinical experiences with small-sized 40-μm TANDEM microspheres, a case report demonstrated a complete response after treatment of a single exophytic HCC of 2.5 cm [56]. More recently, Greco et al [57] reported good tolerance of DEB-TACE using 40-μm TANDEM microspheres loaded with doxorubicin with no adverse event grade III/IV after 73 sessions, and an excellent tumor response with overall response rate (ORR) of 72.6%.…”

Section: Clinical Studiesmentioning

confidence: 99%

Liver Chemoembolization of Hepatocellular Carcinoma using TANDEM ^® Microspheres

et al. 2018

View full text Add to dashboard Cite

Transarterial chemoembolization (TACE) combines intra-arterial delivery of a chemotherapeutic agent with selective embolization to obtain a synergistic effect. TACE is recognized as the standard treatment of hepatocellular carcinoma patients at an intermediate stage. If conventional TACE, defined as the injection of an emulsion of a drug with ethiodized oil, still has a role to play, the development of drug-eluting beads has allowed many improvements and optimization of the technique. TANDEM microspheres are second-generation drug-loadable microspheres. This device raised a special interest due to its tightly calibrated spherical microspheres, with small sizes down to 40 μm available. In this review, we describe the technical characteristics of these microspheres, analyze the scientific literature and hypothesize on the future perspectives.

show abstract

Section: Clinical Studiesmentioning

confidence: 99%

Liver Chemoembolization of Hepatocellular Carcinoma using TANDEM ^® Microspheres

et al. 2018

View full text Add to dashboard Cite

show abstract

“…New evidence suggests that small DC Beads provide a better objective response, downstage the tumor, and produce less tumor necrosis than beads 300-500 μm in size (9). DEBs 40 μm in size (Tandem; CeloNova BioSciences, Newnan, GA) have been used in clinical practice (11). However, beads 300-500 μm in size are common in clinical research.…”

Section: The Diameter Of Debsmentioning

confidence: 99%

Advances in endovascular therapy to treat primary hepatocellular carcinoma

Guo

Liu

et al. 2015

DD&T

View full text Add to dashboard Cite

Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial)

Zhu,

Li,

Sun

et al. 2024

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Purpose While the role of drug-eluting beads transarterial chemoembolization (DEB-TACE) for hepatocellular carcinoma (HCC) is established, questions regarding appropriate bead size for use in patients remain. This trial evaluated the effectiveness and safety of DEB-TACE using small-size (≤ 100 μm) microspheres loaded with epirubicin. Materials and Methods This prospective, single-arm, multicenter study enrolled patients diagnosed with HCC who underwent DEB-TACE using 40 (range, 30–50), 75 (range, 60–90), or 100 (range, 75–125) μm epirubicin-loaded microspheres (TANDEM microspheres, Varian Medical). Bead size was at the discretion of treating physicians and based on tumor size and/or vascular structure. The primary outcome measure was 6-month objective response rate (ORR). Secondary outcome measures were 30-day and 3-month ORR, time to tumor progression and extrahepatic spread, proportion of progression-free survival and overall survival (OS) at one year, and incidence of treatment-associated adverse events. Results Data from 108 patients from ten centers was analyzed. Six-month ORR was 73.3 and 71.3% based on European association for the study of the liver (EASL) and modified response evaluation criteria in solid tumors (mRECIST) criteria, respectively. Thirty-day ORR was 79.6% for both EASL and mRECIST criteria with 3-month ORR being 80.0 and 81.0%, respectively, for each criteria. One-year PPF and OS rate were 60.3 and 94.3%. There was a total of 30 SAEs reported to be likely to definitely associated with microsphere (n = 9), epirubicin (n = 9), or procedure (n = 12) with none resulting in death. Conclusion DEB-TACE using epirubicin-loaded small-sized (≤ 100 μm) microspheres demonstrates promising local tumor control and acceptable safety in patients with HCC. Trial Registration Clinicaltrials.gov NCT03113955; registered April 14, 2017. Trial Registration Clinicaltrials.gov NCT03113955; registered April 14, 2017. Level of evidence 2, Prospective, Non-randomized, Single-arm, study. Graphical Abstract

show abstract

In Vivo Proof of Superselective Transarterial Chemoembolization with 40-μm Drug-Eluting Beads in a Patient with Hepatocellular Carcinoma

Cited by 4 publications

References 6 publications

Liver Chemoembolization of Hepatocellular Carcinoma using TANDEM ^® Microspheres

Liver Chemoembolization of Hepatocellular Carcinoma using TANDEM ^® Microspheres

Advances in endovascular therapy to treat primary hepatocellular carcinoma

Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial)

Contact Info

Product

Resources

About

In Vivo Proof of Superselective Transarterial Chemoembolization with 40-μm Drug-Eluting Beads in a Patient with Hepatocellular Carcinoma

Cited by 4 publications

References 6 publications

Liver Chemoembolization of Hepatocellular Carcinoma using TANDEM ® Microspheres

Liver Chemoembolization of Hepatocellular Carcinoma using TANDEM ® Microspheres

Advances in endovascular therapy to treat primary hepatocellular carcinoma

Transarterial Chemoembolization with Epirubicin-Loaded Microspheres for Hepatocellular Carcinoma: A Prospective, Single-Arm, Multicenter, Phase 2 Study (STOPPER Trial)

Contact Info

Product

Resources

About

Liver Chemoembolization of Hepatocellular Carcinoma using TANDEM ^® Microspheres

Liver Chemoembolization of Hepatocellular Carcinoma using TANDEM ^® Microspheres